Navigation Links
Genesis Pharmaceuticals Reports Results for the Third Quarter of Fiscal Year 2008
Date:5/15/2008

ease tablets and Itopride Hydrochloride Granules as well as sales of Baobaole chewable tablets, which grew rapidly from the time the product was first launched in the second quarter of fiscal year 2008.

Gross profit in the third quarter ended March 31, 2008 totaled $21.8 million, an increase of 60.7% from $13.5 million in the prior year's period. Gross margin was 77.4%, compared to 71.5% in the prior year's period. The increase of gross profit was due to increased sales of higher profit margin products, better control over raw material purchases and more efficient manufacturing.

Research and development expenses in the third quarter ended March 31, 2008 totaled $1.0 million, up slightly from the prior year's period. These research and development expenses were related primarily to payments to the two research institutes with which the Company has collaborative agreements.

Selling, general and administrative expenses in the third quarter ended March 31, 2008 totaled $12.1 million, up 25.6% from $9.7 million in the prior year's period. The majority of this increase was because of an increase in commissions to sales representatives. Starting January, 2008, the Company increased its sales commissions to provide better incentives to its sales representatives. Administrative expenses related to being a public company also increased in fiscal year 2008.

Operating income in the third quarter ended March 31, 2008 totaled $8.7 million, a 195.8% increase from $2.9 million in the prior year's period, representing operating margin of 30.8%.

Other expenses in the third quarter ended March 31, 2008 totaled $2.0 million, compared to $80,000 in the prior year's period. The significant increase in the Company's other expense was related primarily to a $1.2 million unrealized loss on trading securities, a $0.5 million amortization expense on discounted debt and a $0.2 million loss from discontinued operations.

Net income for the third quarter
'/>"/>

SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Cardiogenesis Reports First Quarter 2008 Results
2. Effect of mutant p53 stability on tumorigenesis and drug design
3. Cardiogenesis Corporation to Report 2008 First Quarter Results on May 15th
4. A stem cell type supposed to be crucial for angiogenesis and cancer growth does not exist?
5. Mitochondria play role in pathogenesis of AD and estrogen-induced neuroprotection
6. Science of Sri Vidya Benefits DNA Genesis, Says Dr. Sunita Rana Agarwal
7. Organogenesis Names Regenerative Medicine Expert Dr. Damien Bates Vice President, Medical Affairs
8. Genesis Pharmaceuticals Changes Auditors
9. Cardiogenesis Corporation Announces Rescheduled Fourth Quarter and Full Year 2007 Earnings Release
10. Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call
11. Cardiogenesis Corporation to Report 2007 Fourth Quarter and Year-End Results on March 4th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014 Ticket Down ... Cup Finals tickets at the Sun Life Stadium in ... Champions Cup is now underway. Residents and diehard soccer fans ... to watch the Guinness International Champions Cup final in person ... competing in the tournament have been split into two groups ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Ce-Classes.com ... continues to help healthcare agencies to pass inspections ... and agencies meet their accreditation and state ... based training. , Healthcare administrators can monitor ... clicks of the mouse. Courses can be developed ...
(Date:7/31/2014)... Zensah®, a leading Miami based compression apparel company, ... , designed to help target tennis elbow, elbow tendonitis, ... for summer. The compression elbow sleeve is now available ... Zensah® fabric, the elbow sleeve is made ... no-slip cuff to ensure it stays in place, even ...
(Date:7/31/2014)... To further educate the public, The Rothenberg ... safety information regarding leaving children in hot vehicles: , ... consequences. Because a child’s body can heat up three ... children alone in a hot vehicle puts them at ... Statistics of Children Left Alone in a Car , ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Most mommy ... journals. Mommylish’s main purpose is to attract all mothers ... targeted to a particular group; whether its high fashion ... she realized that everything on the Internet was so ... information on a particular topic and then search Google ...
Breaking Medicine News(10 mins):Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 2Health News:Guinness International Champions Cup Finals Tickets in Miami, FL Available at Ticket Down 3Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 2Health News:Company Helps Healthcare Agencies to Pass Inspections and Audits 3Health News:Compression Elbow Sleeve Provides Relief From Elbow Pain to Golfers and Tennis Players 2Health News:Compression Elbow Sleeve Provides Relief From Elbow Pain to Golfers and Tennis Players 3Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 2Health News:The Rothenberg Law Firm LLP Teams Up with Local Philadelphia TV Stations to Promote Awareness of the Dangers of Leaving Children Unattended in a Hot Vehicle 3Health News:Mommylish Launches Its Website 2
... VANCOUVER, May 15 /PRNewswire-FirstCall/ - CRH Medical Corporation,(CRM:TSX-V) announced ... in Bay Shore, Long Island. This Center is the ... many new markets that CRH has targeted for,expansion. The ... in 2008 bringing the Company,s total number of Centers ...
... N.Y., May 15 Two nutrients found in,certain fruits ... are lutein and zeaxanthin and they are found in ... show that lutein and zeaxanthin not only help prevent ... healthy eyes. For,example, they can improve photostress recovery under ...
... of Global Unified Worklist ... SEATTLE, May 15 Compressus, leaders in ... APC, of,Seattle, announced today an agreement to implement ... data management systems.,The implementation, which will include eight ...
... in mouse model hint of new treatment strategies for the ... polyunsaturated fat, the kind often found in baked and fried ... , The finding by University of California, Los Angeles, scientists ... a mouse model that closely mimics human cancer. , The ...
... PRO-DEX, INC. (Nasdaq:,PDEX) invites shareholders and investors to listen ... quarter financial results, and a discussion,of the outlook for ... be broadcast live over the Internet on,Thursday, May 15, ... accessed by,visiting the Company,s website at http://www.pro-dex.com . ...
... 15 ev3 Inc. (Nasdaq:,EVVV) today announced that Pat ... to present at the 2008 FBR Capital Markets,Spring Investor ... Eastern,Time (1:20 p.m. Central Time and 11:20 a.m. Pacific ... be held at the Grand Hyatt,Hotel, located at 109 ...
Cached Medicine News:Health News:CRH Medical Corporation opens Center in New York 2Health News:Lutein and Zeaxanthin Improve Sports Vision for Athletes 2Health News:Compressus Announces Seattle Radiologists Interoperability Implementation 2Health News:Compressus Announces Seattle Radiologists Interoperability Implementation 3Health News:Lowering Dietary Fat May Help Prevent Prostate Cancer 2Health News:Pro-Dex, Inc. Announces Fiscal 2008 Third Quarter Financial Results Conference Call and Webcast 2
(Date:7/31/2014)... , July 31, 2014 AFFiRiS AG ... York results of AFF008, a Phase I clinical ... the first therapy against the protein alpha-synuclein, a promising Parkinson,s ... J. Fox Foundation for Parkinson,s Research (MJFF) supported the study ... press conference on the impact a disease-modifying therapy would have ...
(Date:7/31/2014)... July 31, 2014 For the first time, ... the implantation of the SynCardia temporary Total Artificial Heart ... video posted on the Journal of Visualized Experiments website. ... the paper on the SynCardia Total Artificial Heart implantation ... accompanies "Implantation of the SynCardia Total Artificial Heart," a ...
(Date:7/31/2014)... NEW YORK , July 31, 2014 ... developing better, faster and affordable treatments for tuberculosis (TB), ... Senior Vice President, Market Access. Ms. Robertson joins the ... the company,s business in Sub-Saharan Africa and ... will oversee the TB Alliance,s efforts to ensure beneficial ...
Breaking Medicine Technology:First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 2First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 3First Clinical Data of Therapeutic Parkinson's Disease Vaccine Encourages Continued Development 4How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 2How to Implant the SynCardia Total Artificial Heart Detailed in Peer Reviewed Paper and Matching Video 3TB Alliance Names Elana Robertson Senior Vice President, Market Access 2TB Alliance Names Elana Robertson Senior Vice President, Market Access 3
... Rapid Fire Marketing (Pink Sheets: RFMK ) announced ... Manufacturer to begin the development of the Pocket Puffer and the ... all specifications are met, the manufacturing facility will set up the ... a patent of the new device once complete and approved. ...
...  Ameritox, the national leader in pain medication monitoring, ... against San Diego-based Millennium Laboratories seeking damages, injunctive ... and unfair trade practices.  The Ameritox filing alleges ... in violations of the Lanham Act, unfair competition ...
Cached Medicine Technology:Rapid Fire Marketing Funds Development of Second Generation Vapor Inhaler 2Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages 2Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages 3
... The TheraSeed® Pd-103 implant is a ... and remarkable visibility that makes TheraSeed® treatment ... You can be confident that every TheraSeed® ... management services which is required by clinicians ...
... BrachyStar® Needle is designed to help you ... clinically effective brachytherapy procedure. All needles are ... and polished surfaces for smooth entry and ... and sizes assures an ideal match with ...
... is a combination of innovative design, consistently ... BrachySource I-125 implant an ideal choice for ... that every BrachySource I-125 implant order is ... is required by clinicians who must meet ...
... temporary internal drainage from the ureteropelvic junction ... stricture. The segment with no sideports prevents ... preventing ingrowth of the ureteral wall to ... Intended for one-time use. CAUTION: Periodic evaluation ...
Medicine Products: